Venmax Drugs and Pharmaceuticals Ltd (VENMAX)

Loading page…

Venmax Drugs and Pharmaceuticals Ltd (VENMAX) · mywealthgrid

About

Venmax Drugs and Pharmaceuticals Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹13 Cr

P/E

—

P/B

0.9×

Dividend yield

ROE

2.7%

ROCE

2.9%

Debt / equity

0.02

OPM

1.4%

EPS (TTM)

₹-0.0

Book value

₹16.0

52-week high

—

52-week low

—

491 historical price candles were omitted because the exchange source has not been verified.

₹14.5-3.2%1Y

Quick read

rule-based

Pros

+Revenue CAGR of 116.1% over the last 5 years
+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of 1.2% (3-yr avg)
−Thin operating margin of 1.4%
−Low promoter holding of 10.5%
−Promoter holding fell 12.7 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

60/100

Business quality: 25
Growth: 55
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2	—	—	—	0	0	0	0	0	1	8
COGS	—	—	—	—	-0	0	0	0	0	1	7
Gross profit	—	—	—	—	—	-0	—	—	—	0	1
	2	—	—	—	1	0	0	0	0	1	1
	-0	—	—	—	-0	-0	-0	-0	-0	-1	0
OPM %	-7.3%	—	—	—	-55.3%	-194.1%	—	—	—	-129.6%	1.4%
Depreciation	—	—	—	—	0	0	0	0	0	0	0
Interest	—	—	—	—	—	0	0	0	0	0	0
	—	—	—	—	—	0	2	0	0	1	0
Profit before tax	-0	-1	-0	-0	-0	-0	2	0	0	-0	0
Tax	—	—	—	—	0	0	0	0	0	0	0
Tax %	—	—	—	—	0%	0%	0%	0%	22.2%	0%	10.7%
	-0	-1	-0	-0	-0	-0	2	0	0	-0	0
PAT margin %	-7.8%	—	—	—	-57.5%	-94.1%	—	—	—	-1.2%	3.1%
EPS (₹)	—	—	-0.5	-0.7	-0.5	-0.3	3.5	0.4	0.1	-0	0.2
EPS adjusted (₹)	—	—	—	—	—	-0.3	3.5	0.4	0.1	-0	0.2
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	5	5	5	5	10	12
Reserves	-8	-6	-6	-6	-6	3
Minority interest	—	—	—	—	—	0
	2	0	0	0	0	0
	1	1	1	0	1	2
Total equity & liabilities	0	0	0	0	5	16
	0	0	0	0	0	0
CWIP	—	—	—	0	0	—
Investments	0	0	0	0	0	0
	0	0	0	0	5	16
Total assets	0	0	0	0	5	16

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	2	0	0	-2	-11
	0	0	0	-0	0	0
	-0	-2	0	0	5	10
Net cash flow	0	-0	0	0	2	-1
Free cash flow	0	2	0	0	-2	-11
CFO / Operating profit %	—	—	—	—	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	-76.5%	—	—	—	2.5%	9.2%
EBITDA margin %	—	-55.3%	-194.1%	—	—	—	-129.6%	1.4%
EBIT margin %	—	-57.4%	-200%	—	—	—	-130.9%	1.4%
PAT margin %	—	-57.5%	-94.1%	—	—	—	-1.2%	3.1%
Working capital
Receivable days	—	—	86	—	—	—	428	65
Inventory days	—	—	0	—	—	—	28	50
Payable days	—	—	560	—	—	—	291	84
NWC days	—	—	-474	—	—	—	165	31
Leverage
Current ratio	—	—	0.07	0.11	0.15	0.03	6.75	7.96
Debt to EBITDA	—	—	—	—	—	—	—	2.55
Debt to equity	—	—	-0.84	-0.37	-0.49	-0.54	0.01	0.02
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0.55	0	0	0	0.16	0.5
Return ratios
Return on assets %	—	—	-51.6%	881%	109.5%	75%	-0.2%	1.5%
Return on capital employed %	—	—	5.8%	-195.7%	-32.4%	-13.8%	-0.2%	2.9%
Return on equity %	—	—	5.8%	-196.8%	-32.4%	-9.2%	-0.2%	1.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	23.13%	23.13%	23.13%	23.13%	23.13%	23.13%	23.13%	23.13%	23.13%	15.14%	13.8%	10.46%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0.15%	0.15%	0.15%	0.15%	0.15%	0.15%	0.15%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	76.72%	76.72%	76.72%	76.72%	76.72%	76.72%	76.72%	76.87%	76.87%	84.86%	86.2%	89.54%
No. of shareholders	—	—	—	—	—	—	—	—	6,764	6,815	6,802	6,865

Promoter holding down 12.67 percentage points since Sep 2023.

20 deals · 19 Dec 2024 – 4 Mar 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
4 Mar 2025	MANASA REDDY DEVIREDDY	Bulk	BSE	Buy	49,998	₹17.51	₹0.09 Cr
4 Mar 2025	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	BSE	Sell	45,155	₹17.51	₹0.08 Cr
4 Mar 2025	SAMTA POLYMERS LTD	Bulk	BSE	Buy	44,820	₹17.51	₹0.08 Cr
4 Mar 2025	SANJAY P PARIKH	Bulk	BSE	Buy	30,000	₹19.35	₹0.06 Cr
4 Mar 2025	KAVITA PARIKH	Bulk	BSE	Buy	30,000	₹19.12	₹0.06 Cr
4 Feb 2025	GREEN PEAKS ENTERPRISES LLP	Bulk	BSE	Buy	47,656	₹30.88	₹0.15 Cr
3 Feb 2025	GREEN PEAKS ENTERPRISES LLP	Bulk	BSE	Sell	59,000	₹29.10	₹0.17 Cr
3 Feb 2025	SUDHANSHU KANDA	Bulk	BSE	Buy	50,000	₹30.28	₹0.15 Cr
3 Feb 2025	RIGHT TIME CONSULTANCY SERVICE PRIVATE LIMITED	Bulk	BSE	Sell	35,000	₹30.28	₹0.11 Cr
3 Feb 2025	DEEPIKAJINDAL	Bulk	BSE	Buy	26,276	₹29.10	₹0.08 Cr

1–10 of 20

1 / 2

Mr. Venkata Rao SadhanalaExecutive Director-Chairperson-MD
Mr. Swapneswar MishraNon-Executive - Non Independent Director
Mr. Dasi Reddy RakeshNon-Executive - Non Independent Director
Mr. Gundluru ReddeppaNon-Executive - Independent Director
Mr. Revoor RamachandraNon-Executive - Independent Director
Mrs. Padmaja kalyani SadhanalaNon-Executive - Non Independent Director
Mr. G Pradeep KumarChief Financial Officer
Mrs. Priyanka AgarwalCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Venmax Drugs and Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results7 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

14 announcementsExport CSV

28 Sept 2026, 2:29 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

22 Sept 2026, 10:13 pmAGM/EGM

NCLT Conveying Shareholder Meeting On October 24, 2026 At 12.30 P.M.

Court Convened Meeting PDF

8 Sept 2026, 2:13 pmCompany Update

Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Scheme of Arrangement PDF

1 Sept 2026, 4:40 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

31 Aug 2026, 5:27 pmBoard Meeting

Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Outcome of Board Meeting PDF

24 Aug 2026, 12:51 pmBoard Meeting

Board Meeting Intimation for Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Exchange filing PDF

8 Aug 2026, 12:43 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

7 Aug 2026, 5:26 pmCompany Update

Statement Of Deviation & Variation

Reg. 32 (1), (3) - Statement of Deviation & Variation PDF

Date	Category	Subject	Filing
28 Sept 2026, 2:29 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
22 Sept 2026, 10:13 pm	AGM/EGM Court Convened Meeting	NCLT Conveying Shareholder Meeting On October 24, 2026 At 12.30 P.M.

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	-76.5%	—	—	—	2.5%	9.2%
EBITDA margin %	—	-55.3%	-194.1%	—	—	—	-129.6%	1.4%
EBIT margin %	—	-57.4%	-200%	—	—	—	-130.9%	1.4%
PAT margin %	—	-57.5%	-94.1%	—	—	—	-1.2%	3.1%
Working capital
Receivable days	—	—	86	—	—	—	428	65
Inventory days	—	—	0	—	—	—	28	50
Payable days	—	—	560	—	—	—	291	84
NWC days	—	—	-474	—	—	—	165	31
Leverage
Current ratio	—	—	0.07	0.11	0.15	0.03	6.75	7.96
Debt to EBITDA	—	—	—	—	—	—	—	2.55
Debt to equity	—	—	-0.84	-0.37	-0.49	-0.54	0.01	0.02
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0.55	0	0	0	0.16	0.5
Return ratios
Return on assets %	—	—	-51.6%	881%	109.5%	75%	-0.2%	1.5%
Return on capital employed %	—	—	5.8%	-195.7%	-32.4%	-13.8%	-0.2%	2.9%
Return on equity %	—	—	5.8%	-196.8%	-32.4%	-9.2%	-0.2%	1.8%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Venmax Drugs and Pharmaceuticals Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

Announcements

Not in the F&O segment

1

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Venmax Drugs and Pharmaceuticals Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Board meetings1

No fund holdings on record

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1